Paclitaxel and encequidar combined to treat breast cancer in key phase 3 clinical study reached the main endpoint
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Today, Athenex(http://announce its oral formula, which combines paclitaxel and encequidar, to reach the main point in a key Phase 3 clinical study to treat metastatic breast cancerAbout Encequidar
Encequidar is a P-gp inhibitorEncequidar is characterized by not being absorbed, so it can partially inhibit the activity of P-gp in the intestines without interacting with P-gp in other parts of the bodyYewalcohol is a widely usedof the(http:// of the widely used chemotherapydrugThis oral formula is comparable to the dose of yew alcohol in patients compared to the widely used 80 mg/m2 weekly intravenous administration programmeThe studya randomized, active-controlled phase 3 clinicaltrial(http://to compare the safety and efficacy of oral yew alcohol monodotherapy with intravenous yew alcohol monotherapy for patients with metastatic breast cancerClinical trial results showed a significant improvement in the primary therapeutic endpoint compared to intravenous yew alcoholThe total remission rate (ORR) was 36% in the oral yew alcohol group, compared with 24% in the intravenous yew alcohol groupIn patients with remission in the oral yew alcohol group, the proportion of patients with remission duration of more than 150 days was 2.5 times that of the intravenous yew alcohol groupThe data showed that oral yew alcohol had no progression survival (PFS) and total survival (OS) was also better than the intravenous group, but the statistical lysiki was not yet statistically significant
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
